Asian Markets Rally as Oil Prices Tumble and Middle East Peace Hopes Emerge 
Bolsonaro Hospitalized in ICU with Bronchopneumonia Amid Calls for House Arrest 
Japan Eyes Oil Futures Intervention to Stabilize Yen Amid Middle East Crisis 
DOJ Antitrust Chief Rejects Political Fast-Track for Paramount-Skydance Deal 
Microsoft Backs Anthropic in Legal Fight Against Pentagon's AI Blacklist 
xAI Faces Federal Lawsuit Over Grok AI-Generated Child Sexual Abuse Material 
Gold Prices Surge on U.S.-Iran Ceasefire Reports 
Time to buy local: war fuel price shocks reveal the folly of a long food supply chain 
Oil Prices Slip as Middle East Tensions Ease, Heading for Weekly Loss 
Asian Currencies Stay Muted as Dollar Holds Firm Amid Iran Uncertainty 
Valero Port Arthur Refinery Explosion Prompts $1M Lawsuit Over Worker Safety Negligence 
Stellantis Shareholder Fraud Lawsuit Dismissed by U.S. Judge 
U.S. Stock Futures Steady as Iran Reviews U.S. Ceasefire Proposal 
Judge Dismisses Sam Altman Sexual Abuse Lawsuit, But Sister Can Refile 
ICE Arrests Colombian Journalist in Tennessee, Trump Administration Says She Will Receive Due Process 
Brazil's Top Court Blocks Trump Official's Visit to Imprisoned Bolsonaro 
Johnson & Johnson disclosed that it spent $800 million in settling "substantially all" of the roughly 9,000 cases by men who claimed having developed excessive breast tissue in using the company's antipsychotic drug Risperdal.
The company said it reached the agreement with lawyers handling the cases, including a lawsuit in Philadelphia by Maryland resident Nicholas Murray, who was awarded an $8 billion in punitive damage by a jury award in 2019. A judge has since reduced the award to $6.8 million.
The lawsuits, filed in Pennsylvania, California, and Missouri, generally accused J&J of failing to warn of the risk called gynecomastia associated with Risperdal, which they claimed were marketed for off-label, unapproved uses with children.
The company denied the allegations.
In 1993, the US Food and Drug Administration approved Risperdal for treating schizophrenia and bipolar mania in adults. It was only in 2006 that it was approved for treating irritability associated with autism in children.
The company separately agreed in 2013 to pay $2.2 billion to settle US criminal and civil probes into its marketing of Risperdal and two other drugs.
In May, the US Supreme Court rejected J&J's bid to overturn a $70 million jury verdict against it for its failure to warn about risks associated with using Risperdal.
